Boston Family Office’s AbbVie ABBV Stock Holding History

Boston Family Office’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$15.5M	Sell	71,162 -61	-0.1%	-$13.5K	1.03%	28
2025 Q4	$16.3M	Sell	71,223 -3,872	-5%	-$882K	1.03%	31
2025 Q3	$17.4M	Buy	75,095 +3,060	+4%	+$623K	1.11%	29
2025 Q2	$13.4M	Sell	72,035 -581	-0.8%	-$108K	0.89%	35
2025 Q1	$15.2M	Sell	72,616 -890	-1%	-$173K	1.08%	31
2024 Q4	$13.1M	Sell	73,506 -1,315	-2%	-$242K	0.9%	33
2024 Q3	$14.8M	Sell	74,821 -45	-0.1%	-$8.4K	1%	32
2024 Q2	$12.8M	Sell	74,866 -2,482	-3%	-$411K	0.93%	34
2024 Q1	$14.1M	Sell	77,348 -1,989	-3%	-$343K	1.01%	31
2023 Q4	$12.3M	Sell	79,337 -1,131	-1%	-$165K	0.92%	31
2023 Q3	$12M	Sell	80,468 -96	-0.1%	-$14.1K	0.98%	31
2023 Q2	$10.9M	Sell	80,564 -2,416	-3%	-$354K	0.83%	37
2023 Q1	$13.2M	Sell	82,980 -1,225	-1%	-$187K	1.06%	30
2022 Q4	$13.6M	Sell	84,205 -71	-0.1%	-$10.9K	1.13%	29
2022 Q3	$11.3M	Sell	84,276 -3,592	-4%	-$515K	1.01%	33
2022 Q2	$13.5M	Sell	87,868 -1,722	-2%	-$263K	1.12%	30
2022 Q1	$14.5M	Buy	89,590 +3,295	+4%	+$479K	1.03%	34
2021 Q4	$11.7M	Sell	86,295 -2,154	-2%	-$254K	0.76%	41
2021 Q3	$9.54M	Buy	88,449 +558	+0.6%	+$63.8K	0.69%	44
2021 Q2	$9.9M	Sell	87,891 -2,088	-2%	-$235K	0.71%	44
2021 Q1	$9.75M	Sell	89,979 -445	-0.5%	-$47.6K	0.73%	48
2020 Q4	$9.69M	Buy	90,424 +6,123	+7%	+$588K	0.75%	47
2020 Q3	$7.38M	Buy	84,301 +11,163	+15%	+$1.05M	0.67%	47
2020 Q2	$7.18M	Sell	73,138 -348	-0.5%	-$30.6K	0.7%	45
2020 Q1	$5.6M	Sell	73,486 -86	-0.1%	-$7.33K	0.66%	46
2019 Q4	$6.51M	Buy	73,572 +225	+0.3%	+$18.7K	0.62%	51
2019 Q3	$5.55M	Sell	73,347 -425	-0.6%	-$29.1K	0.58%	52
2019 Q2	$5.37M	Sell	73,772 -1,191	-2%	-$93.6K	0.56%	55
2019 Q1	$6.04M	Sell	74,963 -1,366	-2%	-$112K	0.65%	49
2018 Q4	$7.04M	Sell	76,329 -9,190	-11%	-$808K	0.87%	43
2018 Q3	$8.09M	Sell	85,519 -1,428	-2%	-$135K	0.85%	40
2018 Q2	$8.06M	Sell	86,947 -752	-0.9%	-$73.4K	0.91%	37
2018 Q1	$8.3M	Sell	87,699 -2,958	-3%	-$325K	0.95%	37
2017 Q4	$8.77M	Sell	90,657 -2,863	-3%	-$270K	0.96%	32
2017 Q3	$8.31M	Sell	93,520 -250	-0.3%	-$19K	0.94%	34
2017 Q2	$6.8M	Sell	93,770 -123	-0.1%	-$8.27K	0.8%	43
2017 Q1	$6.12M	Sell	93,893 -895	-0.9%	-$56.3K	0.75%	45
2016 Q4	$5.94M	Hold	94,788	–	–	0.77%	40
2016 Q3	$5.98M	Buy	94,788 +2,117	+2%	+$137K	0.77%	40
2016 Q2	$5.74M	Buy	92,671 +93	+0.1%	+$5.67K	0.74%	41
2016 Q1	$5.29M	Buy	92,578 +1,757	+2%	+$97.9K	0.7%	47
2015 Q4	$5.38M	Sell	90,821 -2,241	-2%	-$129K	0.74%	42
2015 Q3	$5.06M	Sell	93,062 -300	-0.3%	-$19.5K	0.71%	44
2015 Q2	$6.27M	Sell	93,362 -3,277	-3%	-$214K	0.79%	38
2015 Q1	$5.66M	Sell	96,639 -35	-0%	-$2.11K	0.7%	45
2014 Q4	$6.33M	Buy	96,674 +225	+0.2%	+$14.2K	0.79%	38
2014 Q3	$5.57M	Sell	96,449 -9,712	-9%	-$539K	0.72%	45
2014 Q2	$5.99M	Buy	106,161 +3,143	+3%	+$165K	0.76%	41
2014 Q1	$5.29M	Sell	103,018 -82	-0.1%	-$4.14K	0.7%	48
2013 Q4	$5.45M	Buy	103,100 +2,165	+2%	+$106K	0.72%	46
2013 Q3	$4.51M	Sell	100,935 -2,795	-3%	-$124K	0.64%	51
2013 Q2	$4.29M	Buy	+103,730	New	+$4.54M	0.65%	50

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Boston Family Office's ABBV Position: Q1 2026 in Review

Boston Family Office reduced its AbbVie (ABBV) stake by 0.09% in Q1 2026, selling an estimated $13.5K and leaving 71,162 shares worth $15.5M. The position accounts for 1.03% of the portfolio, ranked #28.

Boston Family Office first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $17.4M in Q3 2025. 4,079 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Boston Family Office held 71,162 shares of AbbVie worth $15.5M as of Q1 2026.
Boston Family Office sold 61 AbbVie shares in Q1 2026, an estimated $13.5K.
AbbVie made up 1.03% of Boston Family Office's portfolio in Q1 2026, its #28 holding.
Boston Family Office first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
Boston Family Office's AbbVie position peaked at $17.4M in Q3 2025.
4,079 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Boston Family Office's 13F filing for Q1 2026, filed 13 May 2026.